Mechanisms of liver injury relevant to pediatric hepatology

M S Tanner1

  • 1Institute of Child Health, University of Sheffield Children's Hospital, Western Bank, UK.

Insights

Pediatric liver disease stems from hepatocyte injury due to toxins, metabolism errors, viruses, and immune issues. Understanding these causes is key for effective treatment and research into childhood liver conditions.

Area of Science:

  • Hepatology
  • Pediatric Gastroenterology
  • Cellular Biology

Background:

  • Hepatocyte injury is a primary driver of pediatric liver disease.
  • Factors influencing hepatocyte injury include liver microenvironment, sepsis, and oxidative stress.
  • Diverse etiological factors contribute to liver damage, including toxins, metabolic disorders, viral infections, and immune responses.

Purpose of the Study:

  • To review the mechanisms of pediatric liver injury.
  • To discuss various causes of liver damage in children, encompassing immune-mediated and genetic disorders.
  • To highlight recent advancements in understanding and treating pediatric liver diseases.

Main Methods:

  • Literature review of immune mechanisms in liver injury.
  • Analysis of monogenic disorders affecting pediatric liver health.
  • Discussion of recent findings on mitochondrial disease, NASH, and cholestatic disorders.

Main Results:

  • Immune mechanisms contribute to liver injury in conditions like autoimmune hepatitis and viral hepatitis.
  • Monogenic disorders such as alpha-1 antitrypsin deficiency and Niemann-Pick C disease exemplify macromolecule retention.
  • Tyrosinemia provides a model for understanding biochemical defects, cell injury, and therapeutic interventions.

Conclusions:

  • Pediatric liver disease arises from complex interactions influencing hepatocyte injury.
  • Understanding specific genetic and immune pathways is crucial for targeted therapies.
  • Ongoing research into various liver conditions promises improved outcomes for affected children.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42